Cytomegalovirus (CMV) is a major pathogen for the neonate and the transplant recipient in both of whom the incidence of the disease and its severity are increased when the donor, or mother, has a primary infection. Many individuals with recurrent infection w~o exp~rience the disease do~because they are being retntected from an exog9ffous source, rather than reactivating their own strain, arguing that natural immunity can reduce, but not completely control, CMV disease. Antiviral therapy is thus needed to control CMV disease. There are four major strategies for the use of drugs against CMV -prophylaxis, suppression, pre-emptive therapy and treatment; significant benefit has been shown for some of these in some groups of transplant patients. The strategies must now be compared, and patient management regimes comparing the various approaches should be considered.
Introduction
Cytomegalovirus (CMV) is recognized as a major pathogen for the neonate and for the immunocompromised patient (Table 1) . To control CMV disease, it is important to understand the natural history of infection and the different pathogenic forms of disease, to optimize diagnostic assays to detect virus at an early stage, to design intervention strategies with antiviral chemotherapy and to conduct placebo-controlled clinical trials with promising drugs. Over the past few years, significant progress has been made in these areas which has produced clinical benefit to patients as well as improving our understanding of pathogenesis.
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Natural history
The host immune response to CMV is deficient in the sense that it can moderate pathology caused by this virus but cannot completely prevent it. Thus, in general, patients experiencing primary infection with CMV are more likely to suffer sequelae than are those experiencing recurrent infection. 'Recurrent' means either reactivation of latent infection or reinfection from an exogenous source. For example, in pregnant women, it is clear that both the incidenceof disease in the neonate and its severity are increased when the mother experiences primary infection as opposedto recurrentinfection (Fowler et al., 1992) .
Similarly, in renal transplant patients primary infection represents more of a threat to the recipient than does recurrent infection (Grundy et al., 1988) although a substantial amount of CMV disease is still experienced by patients in the latter group (Table 2) . Investigators have used molecular biological techniques to show that virus is transmitted to renal transplant recipients from the transplanted organ (Wertheim et al., 1983) and that this infection can be transmitted in the face of pre-existing immunity (Grundy et al., 1988 ). It appears that many of the individuals with recurrent infection who experience disease do so because they are being reinfected from an exogenous source, rather than reactivating their own strain of virus. Thus, the donor is the major source of CMV disease after renal transplant, although reactivation in the recipient still makes a significant contribution to CMV infection.
In contrast, in bone marrow transplant (BMT) patients, most disease originates from reactivation of latent virus in the recipient (Winston et al., 1985) . This does not mean that the donor is irrelevant; it has previously been reported (Grob et al., 1987) that seropositive (immune) donors who are depleted of mature T-cells for prophylaxis against graft-versus-host disease can adoptively transfer some immunity to the recipient (Table 2 ). Since, in these cases, the marrow was depleted of mature T-cells, it can be argued that the protective immunity was not T-cellmediated, and suggests the possibility that humoral immunity may be able to ameliorate disease. More recently, investigators at the Seattle Bone Marrow Transplant Unit have performed a series of elegant studies to show that cytotoxic T-cells from the donor can be propagated in vitro and then infused into the recipient where they persist (Riddell et al., 1992) . This approach appears promising, if rather expensive and time-consuming, and future comparative studies will be required to determine if protection can be afforded.
Pathogenesis

Viral load
Twenty years ago, Stagno et al. (1975) showed that the CMV titre present in the urine at birth in congenitally infected neonates was predictive of future disease outcome. This seminal paper thus represents the first example in human medicine where Virus load was shown to be predictive of future disease. The method used was cell culture, with formal virus titration at repeated intervals, which is clearly an expensive and time-consuming procedure. Furthermore, it could not be applied to immunocompromised transplant patients because the titre of virus that they excrete is significantly lower than that found in neonates. As a result, this author's laboratory has for some years been trying to devise methods that are more sensitive and have a dynamic range sufficient to detect all levels of virus found in clinical material. A method that satisfies these goals has been developed by Dr Vince Emery (Royal Free Hospital Medical School, London), and is known as quantitative-competitive polymerase chain reaction (QPCR) (Fox et al., 1992) . Prospective studies in a cohort of just over 100 renal transplant patients have shown that quantities of CMV in urine can be measured reliably and that the peak amount of virus correlates with disease (Fox et al., 1995) . The difference in median quantity of CMV viruria between those with disease and those who remained asymptomatic is just over 1 log10, a similar difference to that reported earlier in another patient population (Stagno et al., 1975) . This is a very positive finding since it suggests that keeping the peak virus load below a critical level could have a disproportionate effect on controlling CMV disease without controlling CMV infection. Thus, drugs with relatively low activity against CMV and/or vaccines designed to boost humoral immunity could potentially have significant impact on CMV disease.
Immunopathology
Studies in the neonate have shown that the quantity of immune response measured in cord serum is predictive of future disease (Griffiths et el., 1982) . Clearly, this could be an indirect manifestation of virus load but there is no statistical correlation between these two parameters (Griffiths et et., 1982) . This suggests that children may develop disease either because they have a high virus load or because they have an immunopathological response, or both. Future studies will be required to determine if high virus load correlates with one particular clinical presentation, whereas immunopathological responses correlate with another. Likewise, in BMT patients, there is extensive evidence that CMV pneumonitis is immunopathologically mediated. The basis for this is reviewed in a hypothesis article in the Lancet (Grundy et el., 1987) which shows that CMV infection in the lungs of mice does not correlate directly with the presence of disease but that an immune response triggered by the virus causes the pneumonitis. There are obvious ethical constraints preventing identical experiments in man, but a similar phenomenon can be seen in human medicine after BMT (Ruutu et el; . Subsequent studies are consistent with this hypothesis in that the coexistence of graft-versus-host disease increases CMV disease after BMT (Ruutu et a/., 1990) , and the detection of CMV in bronchial washings does not increase the mortality of people with AIDS with or without Pneumocystis carinii infection (Bozzette et a/., 1992) . This indicates that people with AIDS are unable to mount the T-cell response required for immunopathology. However, two cases were identified in a prospective study where high levels of CD4 counts were linked with severe pneumonitis associated with CMV lung infection (Squire et et., 1992) . Evidence suggests that these two patients had HIV seroconversion illness; it is thettefore possible that at this stage patients with HIV inf~~ion may be able to induce CMV immunopathology. >
Viraemia
Another pathogenic marker is the detection of CMV viraemia in transplant patients. It is clear that the detection of CMV from peripheral sites represents a relative risk of approximately 2 for future CMV disease, whereas the detection of viraemia has a relative risk of 6-7 (Meyers et el., 1990; Kidd et a/., 1993) . This is true whether the viraemia is detected by cell culture (Meyers et sl., 1990) or by PCR (Kidd et a/., 1993) . Presumably, viraemia results from the failure of local immune control of a focus of CMV infection and allows dissemination of virus to target organs.
Treatment strategies
Given this background, there are four major strategies for the use of drugs against CMV (Table 3 ). Furthermore, on first principles, one can also suggest that the side-effects of drugs would have to meet certain criteria before being eligible for use in each of the strategies (Table 3) . For example, the risk of CMV disease is low in any given transplant patient so that the administration of a drug prophylactically to all transplant patients could only be justified if the drug had no clinically significant toxicity. The drugs that have been evaluated so far in double-blind, placebo-controlled trials are listed in Table 4 ; their important features are discussed below. Meyers et at. (1988) were the first to show that highdose intravenous aciclovir given from 5 days before to 30 CMV management 9 days after BMT was able to reduce CMV disease and also to provide a survival benefit. This result was controversial because investigators, at that time, did not consider aciclovir to have useful anti-CMV activity and the trial was not randomized. However, a recent report (Prentice et a/., 1994) randomly allocated BMT patients to three treatment arms and confirmed the survival benefit originally described by Meyers et at. in 1988 . The high-dose aciclovir used in this patient population significantly reduced CMV disease and CMV as a cause of death. However, not all of the survival benefit can be attributed numerically to the reduced number of deaths ascribed to CMV. One possibility is that the underlying CMV infection may precipitate death by facilitating secondary bacterial and/or fungal infections so that these subsidiary events are recorded clinically as the cause of death, rather than the underlying CMV infection. This possibility is supported by the finding that inhibition of CMV viraemia correlates statistically with the survival benefit (Prentice et aI., 1994) .
In renal transplant patients, Balfour et at. (1989) gave oral aciclovir, 800 mg qds for 12 weeks, and showed a significant reduction in CMV disease. The effect was most marked among patients who were donor-seropositive but recipient-seronegative, l.e. having primary infection after renal transplant. Interesting pharmacokinetic studies were conducted to show that the peak level of aciclovir was about 25 J..lM and the trough 18 J..lM; renal transplant patients thus had higher levels than found in normals, presumably because their renal insufficiency was delaying excretion of the drug. Despite these high levels, the values did not approach the mean ID 5 0 for the CMV strains isolated from the same patients, which was around 63 J..lM (Balfour et a/., 1989) . The fact that the drug was shown to improve CMV disease compared to placebo suggests that the viruses in the patients did respond to the drug and leads to the inevitable conclusion that the Bone marrow Renal Heart GCV Reed etal., 1990 GCV Goodrich et al., 1991 IFN Cheeseman et al., 1979 Hirsch et al., 1983 Lui et al., 1992 ACV Prentice et al., 1994 Balfour et al., 1989 Ig Metselaar et al., 1989 GCV Winston etal., 1993 Merigan, 1992 Goodrich, et al., 1993 Treatment Pre-emptive Suppression Prophylaxis Table 4 . Double-blind placebo-controlled trials against cytomegalovirus in transplant patients Strategy ----------------------------- GCV, ganciclovir; ACV, aciclovir; Ig, immunoglobulin; IFN, interferon. laboratory assay used does not give values that are representative of the situation in vivo. In this regard, it should be noted that aciclovir triphosphate is a potent inhibitor of CMV DNA polymerase (Mar et el., 1985) and the UL97 gene products of CMV can phosphorylate aciclovir as well as ganciclovir (Littler et a/., 1992; Sullivan et a/., 1992) . Ganciclovir has also been used prophylactically. In a series of heart transplant patients, Merigan et at. (1992) showed that CMV disease was significantly reduced by ganciclovir prophylaxis, but only in those patients who were initially seropositive, not in those seronegative patients at risk of primary infection because they had seropositive donors. In two BMT populations, ganciclovir prophylaxis given once the bone marrow had eng rafted was shown to have a marked effect on CMV disease, yet to have no survival benefit (Goodrich et el., 1993; Winston et a/., 1993) . This suggests that the toxicity of ganci-c1ovir, particularly the neutropenia, outweighs its potent effect on CMV disease when given prophylactically to large numbers of patients; there is some statistical evidence for this (Goodrichet a/., 1993) .
In contrast, when ganciclovir was given only to patients who were excreting CMV after BMT, significant reductions in CMV disease were reported, together with a significant reduction in mortality (Goodrich et a/., 1991) . This demonstrates clearly that, although ganciclovir is too toxic to use in the prophylactic mode, it can provide significant clinical benefit when used for suppression.
Conclusions
Emerging knowledge of the natural history and pathogenesis of CMV disease in transplant patients has led to the conduct of several controlled clinical trials. Significant clinical benefit has been shown for some of these. What is now required is comparison of different strategies, e.g. comparisi on of aciclovir prophylaxis with ganciclovir suppression, and comparision of valaciclovir prophylaxis with ganciclovir suppression in BMT patients. In addition, patient management strategies combining the various approaches should be considered. For example, a protocol could be designed where patients cascade through each of the intervention strategies. Thus, if they fail prophylaxis, as shown by the detection of virus, they are then put on suppression, and if they fail this, as shown by the detection of viraemia, they then go on to pre-emptive therapy, and finally go on to treatment if all earlier approaches have failed. Such an approach has the potential finally to bring CMV disease under control in transplant recipients. Evaluation of this possibility will require the collaboration of many transplant centres which currently have distinct protocols for managing CMV.
